Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lesson Learned
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(198)
•••
Comment by Pragmatiston Feb 18, 2021 2:21am
235 Views
Post# 32593031

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lesson Learned

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lesson Learned
Doccole wrote:

Lol so true!

I just don't get it.  I understand the the raise purpose.  I guess I was hoping to acquire enough $ through deals to fund phase 3.  Which the CEO insinuated the fireside chats.  Dude Is Very misleading. 



Those were my initial thoughts too, Doc.  Not only the fireside chats, but from what was implied in the shelf prospectus and other statements as well. 
 
We were not expecting an equity raise this soon, if at all. Dan has always been a straightshooter. He thought that a partner would fund PH 3. So it was a bit of a curve to hear this now. 
 
It is for this reason that I think that when Dan has an opportunity to explain this, he will say that the PO price was agreed to a few days back when the SP was lower, that there was a short fuze involved, and that it presented a favorable opportunity to raise cash at very favorable terms.  
 
In this vein he could be right. And it might be a good call. I guess we will soon see.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities